生物技术公司Moderna近日披露，美国食品药品监督管理局（FDA）已向其研发中的季节性流感疫苗mRNA-1010发出拒收函。这意味着监管机构认为该公司提交的申请材料存在不完整之处，尚不符合受理标准。
生物技术公司Moderna近日披露，美国食品药品监督管理局（FDA）已向其研发中的季节性流感疫苗mRNA-1010发出拒收函。这意味着监管机构认为该公司提交的申请材料存在不完整之处，尚不符合受理标准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.